| Androgen receptor splice variants determine taxane sensitivity in prostate cancer M Thadani-Mulero, L Portella, S Sun, M Sung, A Matov, RL Vessella, ... Cancer research 74 (8), 2270-2282, 2014 | 267 | 2014 |
| Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in … ST Tagawa, ES Antonarakis, A Gjyrezi, G Galletti, S Kim, D Worroll, ... Clinical Cancer Research 25 (6), 1880-1888, 2019 | 111 | 2019 |
| Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer C D'alterio, C Consales, M Polimeno, R Franco, L Cindolo, L Portella, ... Current cancer drug targets 10 (7), 772-781, 2010 | 107 | 2010 |
| Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases L Portella, R Vitale, S De Luca, C D’Alterio, C Ierano, M Napolitano, ... PloS one 8 (9), e74548, 2013 | 95 | 2013 |
| Randomized, noncomparative, phase II trial of early switch from docetaxel to cabazitaxel or vice versa, with integrated biomarker analysis, in men with chemotherapy-naive … ES Antonarakis, ST Tagawa, G Galletti, D Worroll, K Ballman, ... Journal of Clinical Oncology 35 (28), 3181, 2017 | 83 | 2017 |
| Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1 C D’Alterio, M Buoncervello, C Ieranò, M Napolitano, L Portella, G Rea, ... Journal of Experimental & Clinical Cancer Research 38, 1-13, 2019 | 79 | 2019 |
| Regulatory T cells, interleukin (IL)‐6, IL‐8, V ascular endothelial growth factor (VEGF), CXC L10, CXC L11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as … M Polimeno, M Napolitano, S Costantini, L Portella, A Esposito, F Capone, ... BJU international 112 (5), 686-696, 2013 | 74 | 2013 |
| Differential role of CD133 and CXCR4 in renal cell carcinoma C D’Alterio, L Cindolo, L Portella, M Polimeno, C Consales, A Riccio, ... Cell Cycle 9 (22), 4492-4500, 2010 | 74 | 2010 |
| Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential G Galletti, L Portella, ST Tagawa, BJ Kirby, P Giannakakou, DM Nanus Molecular diagnosis & therapy 18, 389-402, 2014 | 71 | 2014 |
| Inhibition of stromal CXCR4 impairs development of lung metastases C D’Alterio, A Barbieri, L Portella, G Palma, M Polimeno, A Riccio, ... Cancer Immunology, Immunotherapy 61, 1713-1720, 2012 | 68 | 2012 |
| Ionizing radiation effects on the tumor microenvironment L Portella, S Scala Seminars in Oncology 46 (3), 254-260, 2019 | 60 | 2019 |
| CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not M Neve Polimeno, C Ierano, C D'alterio, N Simona Losito, M Napolitano, ... Cellular & molecular immunology 12 (4), 474-482, 2015 | 54 | 2015 |
| CXCL12 signaling in the tumor microenvironment L Portella, AM Bello, S Scala Tumor Microenvironment: The Role of Chemokines–Part B, 51-70, 2021 | 35 | 2021 |
| High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer C D'Alterio, L Portella, A Ottaiano, M Rizzo, G Carteni, S Pignata, ... Current Cancer Drug Targets 12 (6), 693-702, 2012 | 35 | 2012 |
| In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies C Ieranò, D Righelli, C D'Alterio, M Napolitano, L Portella, G Rea, ... Journal for Immunotherapy of Cancer 10 (3), 2022 | 32 | 2022 |
| Exploring the N-terminal region of CXC motif chemokine 12 (CXCL12): identification of plasma-stable cyclic peptides as novel, potent CXC chemokine receptor type 4 (CXCR4 … S Di Maro, AM Trotta, D Brancaccio, FS Di Leva, V La Pietra, C Ierano, ... Journal of Medicinal Chemistry 59 (18), 8369-8380, 2016 | 31 | 2016 |
| Ligand-based NMR study of CXC chemokine receptor type 4 (CXCR4)–ligand interactions on living cancer cells D Brancaccio, D Diana, S Di Maro, FS Di Leva, S Tomassi, R Fattorusso, ... Journal of Medicinal Chemistry 61 (7), 2910-2923, 2018 | 25 | 2018 |
| CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis C Ieranò, L Portella, S Lusa, G Salzano, C D'Alterio, M Napolitano, ... Nanoscale 8 (14), 7562-7571, 2016 | 24 | 2016 |
| Structure–activity relationships and biological characterization of a novel, potent, and serum stable CXC chemokine receptor type 4 (CXCR4) antagonist S Di Maro, FS Di Leva, AM Trotta, D Brancaccio, L Portella, M Aurilio, ... Journal of Medicinal Chemistry 60 (23), 9641-9652, 2017 | 23 | 2017 |
| A novel CXCR4-targeted near-infrared (NIR) fluorescent probe (Peptide R-NIR750) specifically detects CXCR4 expressing tumors S Santagata, L Portella, M Napolitano, A Greco, C D’Alterio, MV Barone, ... Scientific Reports 7 (1), 2554, 2017 | 18 | 2017 |
Stefania ScalaOncology- ImmunologyVerified email at istitutotumori.na.it
